15 June 2022 in Journal of Pathology and Translational Medicine
Background: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches.Methods: Spearman’s correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients’ samples, and was associated with clinicopathological data and overall survival.Results: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase–Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041).Conclusions: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology.
20 May 2014 in Journal of Clinical Oncology
COCamila Borges Martins Oliveira
Camila Borges Martins Oliveira
LBLeonardo Da Silveira Bossi
Leonardo Da Silveira Bossi
+2
584 Background: ERP29, a tumor suppressor gene, was related with the onset of tumors. The influence of ERP29 c.*293A>G (rs7114) polymorphism in breast cancer (BC) risk and prognosis has never been performed before and was the aim of this study. Methods: We analyzed 742 BC patients and 742 healthy women. The BC patients were treated by conventional procedures. ERP29 c.*293A>G genotypes were obtained from genomic DNA by TaqMan genotyping assays. The expression of ERP29 mRNA was determined by quantitative PCR using total RNA from blood leukocytes of healthy individuals with distinct genotypes (12 individuals with AA, 15 with AG, and six with GG). Overall survival (OS) was obtained from date of first diagnosis until the date of death or last follow-up. The differences in frequencies of distinct genotypes in patients and controls were analyzed by logistic regression model, serving to obtain age, ethnic origin and adjusted crude odds ratios (ORs), considering a confidence interval (CI) of 95%. OS time was calcu...
11 November 2017 in Arquivos Brasileiros de Cirurgia Digestiva Express